白雲山(00874.HK)出資3.3億人幣參與設立沃博聯廣藥基金
白雲山(00874.HK)公布,於3月2日董事會批准公司作為主要投資人出資9.99億元人民幣(下同)設立的廣藥基金出資3.34億元參與設立沃博聯廣藥基金,並同意廣藥基金與廣藥資本、聯合美華及沃博聯亞洲投資簽署合作協議。同日,廣藥基金與協議相關方共同簽署了合作協議。
目前公司控股股東廣藥集團持有廣藥資本80%的權益。沃博聯廣藥基金為於中國註冊的有限合夥,從事股權投資、投資管理、資產管理等活動,主要聚焦生物醫藥健康領域的股權投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.